Rezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream. Herein, three patient cases are presented from an academic medical center. Infectious processes presented include drug-resistant mucosal candidiasis, prosthetic joint infection, and candidemia involving Candida auris. In all three cases, patients received rezafungin. Clinical response was demonstrated in all patients as was tolerability of rezafungin. Together these cases provide further evidence for the use of rezafungin, including its use for treatment of invasive infections other than candidemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40121-025-01120-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
It's Here, It's There, There's Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis.
Infect Dis Ther
March 2025
Department of Medicine, Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA.
Rezafungin is a long-acting echinocandin with broad coverage against Candida. Rezafungin has primarily been indicated for candidemia, with limited literature available on its use for infections outside of the bloodstream. Herein, three patient cases are presented from an academic medical center.
View Article and Find Full Text PDFActivity of Rezafungin Against Echinocandin Non-wild type Clinical Isolates From a Global Surveillance Program.
Open Forum Infect Dis
March 2025
Element Iowa City (JMI Laboratories), North Liberty, Iowa USA.
Among 1463 isolates collected in 39 US hospitals, 91 (6.2%) were non-wild type to ≥1 echinocandins (ECH-NWT) when tested by the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method and interpretative criteria. Rezafungin breakpoints established by the US Food and Drug Administration (FDA) were also applied.
View Article and Find Full Text PDFAntifungal pipeline: New tools for the treatment of mycoses.
Rev Iberoam Micol
February 2025
Center for Dermatological Diseases, Ministry of Public Health and Social Welfare, San Lorenzo, Paraguay.
Fungal infections are becoming an escalating public health challenge, particularly among immunocompromised individuals. The partially limited efficacy of current antifungal treatments, their potential adverse effects, and the increasing problem of resistance emphasize the need for new treatment options. Existing antifungal classes-allylamines, azoles, echinocandins, polyenes, and pyrimidine analogs-face challenges due to their similarity with human cells and rising resistance.
View Article and Find Full Text PDFRezafungin in special populations with candidaemia and/or invasive candidiasis.
J Infect
March 2025
Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Department of Internal Medicine, Medical University of Graz, Graz, Austria. Electronic address:
Achieving and maintaining therapeutic drug exposures with antifungals can be challenging in special patient populations, such as those with organ dysfunction (liver or kidney) or obesity, or elderly patients, due to dose-exposure relationships and potential drug-drug interactions. Dose adjustments may be needed in these populations to maintain therapeutic efficacy and/or prevent toxicity. We reviewed specific dosing considerations for antifungals in special populations with candidaemia and/or invasive candidiasis, focusing on those relating to echinocandins (based on prescribing information), and then explored the utility of the second-generation echinocandin rezafungin in treating these populations (based on currently available data identified from a PubMed and congress abstract search).
View Article and Find Full Text PDFRezafungin: A Review in Invasive Candidiasis.
Drugs
March 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Rezafungin (Rezzayo) is a next-generation echinocandin antifungal with improved pharmacokinetic properties over first-generation echinocandins that allows for once-weekly rather than once-daily intravenous administration. It has recently been approved for the treatment of adults with invasive candidiasis in the EU and UK, and is approved for adults who have limited or no alternative options for the treatment of candidaemia and invasive candidiasis in the USA. In the pivotal phase 3 ReSTORE trial, rezafungin was non-inferior to caspofungin (a first-line echinocandin antifungal agent) based both on global cure rates at day 14 and all-cause mortality rates at day 30 in adults with candidaemia or invasive candidiasis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!